[go: up one dir, main page]

AR122096A2 - Compuestos profármacos de creatina y composiciones que los comprenden - Google Patents

Compuestos profármacos de creatina y composiciones que los comprenden

Info

Publication number
AR122096A2
AR122096A2 ARP210101331A ARP210101331A AR122096A2 AR 122096 A2 AR122096 A2 AR 122096A2 AR P210101331 A ARP210101331 A AR P210101331A AR P210101331 A ARP210101331 A AR P210101331A AR 122096 A2 AR122096 A2 AR 122096A2
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
replacement
cycloalkyl
arilalquilo
Prior art date
Application number
ARP210101331A
Other languages
English (en)
Inventor
William F Brubaker
Original Assignee
Farmington Pharma Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmington Pharma Dev filed Critical Farmington Pharma Dev
Publication of AR122096A2 publication Critical patent/AR122096A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos profármacos de creatina, composiciones farmacéuticas que los comprenden y el empleo de los mismos para el tratamiento de enfermedades neurodegenerativas, de la isquemia y para la homeostasis energética en un tejido u órgano entre otros usos. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1), fórmula (3), fórmula (5), o una sal, solvato, tautómero o estereoisómero farmacéuticamente aceptable de este: donde el compuesto de la fórmula (1) es: como se muestra a continuación, donde: R es -CH₃ o -CD₃; R¹ es hidrógeno, -OR², -C(O)OR², -C(O)R², o un resto del grupo de fórmulas (2); n es un entero de 1 a 2; cada R² es independientemente hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀ o heteroarilalquilo C₆₋₂₀ sustituido; cada R³ y R⁴ es independientemente hidrógeno, alquilo C₁₋₁₂ o alquilo C₁₋₁₂ sustituido; R²³ es hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, cicloalquilo C₅₋₁₂, cicloalquilo C₅₋₁₂ sustituido, arilo C₅₋₁₂, y arilo C₅₋₁₂ sustituido, -C(O)-OR²² o -C(O)-R²²; R²² es alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀ o heteroarilalquilo C₆₋₂₀ sustituido; y R⁴⁸ es alquilo C₁₋₁₂ o alquilo C₁₋₁₂ sustituido; donde el compuesto de la fórmula (3) es: como se muestra a continuación, donde: R es -CH₃ o -CD₃; R¹⁰ es hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀, heteroarilalquilo C₆₋₂₀ sustituido, -C(O)R⁵, -C(O)OR⁵, -C(O)(NR³R⁴), -C(R³R⁴)-C(O)OR²², -C(R³R⁴)-(O)C(O)R²², -C(R³R⁴)-(O)C(O)-OR²²; o un resto del grupo de fórmulas (4); cada uno de R¹¹ y R¹² es independientemente hidrógeno o -OR¹³; o cada uno de R¹¹ y R¹² es -C(O)R⁵, con la condición de que ambos R¹¹ y R¹² no puedan ser hidrógeno; R¹³ es independientemente hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀, heteroarilalquilo C₆₋₂₀ sustituido, -CH(OR⁵), -C(O)R⁵, -C(O)OR⁵ o -C(O)(NR³R⁴); cada R³ y R⁴ es independientemente hidrógeno, alquilo C₁₋₁₂ o alquilo C₁₋₁₂ sustituido; R⁵ es hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀ o heteroarilalquilo C₆₋₂₀ sustituido; R²³ es hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, cicloalquilo C₅₋₁₂, cicloalquilo C₅₋₁₂ sustituido, arilo C₅₋₁₂, y arilo C₅₋₁₂ sustituido, -C(O)-OR²² o -C(O)-R²²; R²² es alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀ o heteroarilalquilo C₆₋₂₀ sustituido; y n es un entero de 1 a 2; donde el compuesto de la fórmula (5) es: como se muestra a continuación, donde: R es -CH₃ o -CD₃; cada R¹⁴ es independientemente hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀, heteroarilalquilo C₆₋₂₀ sustituido, -CH(OR⁵), -C(O)R⁵, -C(O)OR⁵ o -C(O)(NR³R⁴); cada R³ y R⁴ es independientemente hidrógeno, alquilo C₁₋₁₂ o alquilo C₁₋₁₂ sustituido; y R⁵ es hidrógeno, alquilo C₁₋₁₂, alquilo C₁₋₁₂ sustituido, heteroalquilo C₁₋₁₂, heteroalquilo C₁₋₁₂ sustituido, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂ sustituido, cicloalquilalquilo C₄₋₂₀, cicloalquilalquilo C₄₋₂₀ sustituido, heterocicloalquilalquilo C₄₋₂₀, heterocicloalquilalquilo C₄₋₂₀ sustituido, arilo C₅₋₁₂, arilo C₅₋₁₂ sustituido, heteroarilo C₅₋₁₂, heteroarilo C₅₋₁₂ sustituido, arilalquilo C₆₋₂₀, arilalquilo C₆₋₂₀ sustituido, heteroarilalquilo C₆₋₂₀ o heteroarilalquilo C₆₋₂₀ sustituido.
ARP210101331A 2014-12-22 2021-05-14 Compuestos profármacos de creatina y composiciones que los comprenden AR122096A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462095295P 2014-12-22 2014-12-22

Publications (1)

Publication Number Publication Date
AR122096A2 true AR122096A2 (es) 2022-08-10

Family

ID=56128653

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150104265A AR103254A1 (es) 2014-12-22 2015-12-22 Profármacos de creatina, composiciones y métodos de uso de estos
ARP210101331A AR122096A2 (es) 2014-12-22 2021-05-14 Compuestos profármacos de creatina y composiciones que los comprenden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP150104265A AR103254A1 (es) 2014-12-22 2015-12-22 Profármacos de creatina, composiciones y métodos de uso de estos

Country Status (8)

Country Link
US (3) US9617230B2 (es)
EP (2) EP3771709B1 (es)
JP (4) JP6692372B2 (es)
AR (2) AR103254A1 (es)
CA (1) CA2971729C (es)
ES (1) ES2832333T3 (es)
TW (3) TWI700270B (es)
WO (1) WO2016106284A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016160885A1 (en) 2015-03-30 2016-10-06 Farmington Pharma Development Creatine phosphate analog prodrugs, compositions and uses thereof
US11332438B2 (en) 2017-12-01 2022-05-17 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
CN110746325A (zh) * 2018-07-24 2020-02-04 上海和辉光电有限公司 一种基于胍骨架的n型掺杂化合物及其应用
CN114419050B (zh) * 2022-03-31 2022-06-21 武汉大学 胃黏膜可视化程度量化方法、装置、终端及可读存储介质

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
EP0595894B1 (en) 1991-07-19 1995-12-20 UNIROYAL CHEMICAL COMPANY, Inc. Seed film compositions
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
AU4151996A (en) 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
JPH11513671A (ja) 1995-10-11 1999-11-24 アヴィセナ グループ，インク． 糖代謝異常の治療のためのクレアチン類似体の利用
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6008252A (en) * 1996-07-26 1999-12-28 Beale; Paxton K. Method for increasing muscle mass in a mammal
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
JP2001527023A (ja) 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US20030008007A1 (en) 2001-04-23 2003-01-09 Jose Gutierrez-Rocca Release pharmaceutical construct for gastric retention
US20030013767A1 (en) 2001-07-13 2003-01-16 Samuel Bessman Method of treating weight loss using creatine
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2002363998A1 (en) 2001-12-15 2003-06-30 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
MXPA04006545A (es) 2002-01-03 2004-10-04 Smithkline Beecham Corp Nuevas formas de dosificacion farmaceutica y metodo para producir las mismas.
DE10221344A1 (de) 2002-05-14 2003-12-04 Hannover Med Hochschule Transgene Ratte und ihre Verwendung im Tiermodell für die humane Chorea Huntington Erkrankung sowie Nukleinsäurekonstrukte, Vektoren und Zellen zu ihrer Erzeugung
JP2006502976A (ja) 2002-05-17 2006-01-26 エスペリオン セラピューティクス，インコーポレイテッド 虚血再潅流を治療する方法および組成物
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
EP1524963A2 (en) 2002-06-26 2005-04-27 Cadila Healthcare Ltd. Novel floating dosage form
US20040120983A1 (en) * 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US20070012105A1 (en) 2005-07-13 2007-01-18 Barnes-Jewish Hospital Method and apparatus for resistive characteristic assessment
US20070032750A1 (en) 2005-07-15 2007-02-08 Jeffrey Oster Muscle strength assessment system
US7683043B2 (en) 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
WO2007146086A1 (en) * 2006-06-06 2007-12-21 Xenoport, Inc. Creatine prodrugs, compositions and uses thereof
US20070281909A1 (en) 2006-06-06 2007-12-06 Xenoport, Inc. Creatine phosphate prodrugs, compositions and uses thereof
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
US7319157B1 (en) 2007-02-20 2008-01-15 Multi Formulations Ltd. Creatine-fatty acids
US8546369B2 (en) 2008-05-30 2013-10-01 Northern Innovations Holding Corp. Salts of creatine imino sugar amides
WO2010005692A2 (en) 2008-06-16 2010-01-14 E. I. Du Pont De Nemours And Company Insecticidal cyclic carbonyl amidines
CN103889993B (zh) * 2011-09-19 2017-05-31 吉奇亚公司 修饰的肌酸化合物
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
ES2590708T3 (es) * 2012-07-30 2016-11-23 Commissariat à l'énergie atomique et aux énergies alternatives Método para preparar ésteres grasos de creatina, ésteres grasos de creatina preparados de este modo y usos de los mismos
ITTO20121098A1 (it) * 2012-12-18 2014-06-19 Univ Degli Studi Genova Procedimento per sintetizzare derivati della creatina
US20160289175A1 (en) * 2013-11-05 2016-10-06 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
ITTO20131070A1 (it) * 2013-12-24 2015-06-25 Univ Degli Studi Genova Applicazione terapeutica di un derivato di creatina
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016110822A1 (en) * 2015-01-09 2016-07-14 Universita' Degli Studi Di Genova Carboxylic biacyl creatine derivative, uses and method of synthesis thereof
WO2016160885A1 (en) 2015-03-30 2016-10-06 Farmington Pharma Development Creatine phosphate analog prodrugs, compositions and uses thereof

Also Published As

Publication number Publication date
TWI700270B (zh) 2020-08-01
US9617230B2 (en) 2017-04-11
AR103254A1 (es) 2017-04-26
TW201629011A (zh) 2016-08-16
JP2020128379A (ja) 2020-08-27
TWI832450B (zh) 2024-02-11
JP7676338B2 (ja) 2025-05-14
EP3237391B1 (en) 2020-09-02
US20160176829A1 (en) 2016-06-23
US10344007B2 (en) 2019-07-09
TW202304854A (zh) 2023-02-01
JP2018502911A (ja) 2018-02-01
ES2832333T3 (es) 2021-06-10
WO2016106284A3 (en) 2016-10-13
US11407722B2 (en) 2022-08-09
EP3237391A4 (en) 2018-10-03
JP2022078213A (ja) 2022-05-24
EP3771709B1 (en) 2024-03-20
JP2025118733A (ja) 2025-08-13
EP3771709A1 (en) 2021-02-03
EP3771709C0 (en) 2024-03-20
TW202041504A (zh) 2020-11-16
EP3237391A2 (en) 2017-11-01
JP6692372B2 (ja) 2020-05-13
WO2016106284A2 (en) 2016-06-30
JP7037597B2 (ja) 2022-03-16
CA2971729A1 (en) 2016-06-30
US20170342039A1 (en) 2017-11-30
US20190337909A1 (en) 2019-11-07
CA2971729C (en) 2024-02-20
TWI779312B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
AR122096A2 (es) Compuestos profármacos de creatina y composiciones que los comprenden
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2017007284A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas.
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR097325A1 (es) Pirroles anillados
AR094550A1 (es) Inhibidores de btk
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
CU24392B1 (es) Compuestos y composiciones para inducir condrogénesis
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
MX2017016370A (es) Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
AR111271A1 (es) Inhibidores dobles de magl y faah
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
AR097773A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa